vs
PHIBRO ANIMAL HEALTH CORP（PAHC）とPOWER SOLUTIONS INTERNATIONAL, INC.（PSIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $191.2M、POWER SOLUTIONS INTERNATIONAL, INC.の約2.0倍）。POWER SOLUTIONS INTERNATIONAL, INC.の純利益率が高く（8.4% vs 7.3%、差は1.1%）。POWER SOLUTIONS INTERNATIONAL, INC.の前年同期比売上増加率が高い（32.5% vs 20.9%）。PHIBRO ANIMAL HEALTH CORPの直近四半期フリーキャッシュフローが多い（$8.3M vs $-7.6M）。過去8四半期でPOWER SOLUTIONS INTERNATIONAL, INC.の売上複合成長率が高い（41.7% vs 19.2%）
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
アダニ・エナジー・ソリューションズ株式会社（旧称：アダニ送電株式会社）は電力の送配電事業を営む企業で、本社はアフマダーバードに所在します。2025年4月時点で累計26,696回路キロメートルの送電網を運用しており、インド最大級の民間部門送電会社の1つです。
PAHC vs PSIX — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $373.9M | $191.2M |
| 純利益 | $27.5M | $16.1M |
| 粗利率 | 35.5% | 21.9% |
| 営業利益率 | 13.5% | 12.7% |
| 純利益率 | 7.3% | 8.4% |
| 売上前年比 | 20.9% | 32.5% |
| 純利益前年比 | 762.1% | -31.0% |
| EPS（希薄化後） | $0.67 | $0.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $373.9M | $191.2M | ||
| Q3 25 | $363.9M | $203.8M | ||
| Q2 25 | $378.7M | $191.9M | ||
| Q1 25 | $347.8M | $135.4M | ||
| Q4 24 | $309.3M | $144.3M | ||
| Q3 24 | $260.4M | $125.8M | ||
| Q2 24 | $273.2M | $110.6M | ||
| Q1 24 | $263.2M | $95.2M |
| Q4 25 | $27.5M | $16.1M | ||
| Q3 25 | $26.5M | $27.6M | ||
| Q2 25 | $17.2M | $51.2M | ||
| Q1 25 | $20.9M | $19.1M | ||
| Q4 24 | $3.2M | $23.3M | ||
| Q3 24 | $7.0M | $17.3M | ||
| Q2 24 | $752.0K | $21.5M | ||
| Q1 24 | $8.4M | $7.1M |
| Q4 25 | 35.5% | 21.9% | ||
| Q3 25 | 32.9% | 23.9% | ||
| Q2 25 | 29.0% | 28.2% | ||
| Q1 25 | 30.1% | 29.7% | ||
| Q4 24 | 32.9% | 29.9% | ||
| Q3 24 | 32.1% | 28.9% | ||
| Q2 24 | 31.9% | 31.8% | ||
| Q1 24 | 30.2% | 27.0% |
| Q4 25 | 13.5% | 12.7% | ||
| Q3 25 | 14.1% | 13.9% | ||
| Q2 25 | 8.9% | 16.9% | ||
| Q1 25 | 9.6% | 18.2% | ||
| Q4 24 | 8.3% | 17.5% | ||
| Q3 24 | 6.8% | 16.3% | ||
| Q2 24 | 6.7% | 22.9% | ||
| Q1 24 | 7.6% | 11.2% |
| Q4 25 | 7.3% | 8.4% | ||
| Q3 25 | 7.3% | 13.5% | ||
| Q2 25 | 4.5% | 26.7% | ||
| Q1 25 | 6.0% | 14.1% | ||
| Q4 24 | 1.0% | 16.1% | ||
| Q3 24 | 2.7% | 13.8% | ||
| Q2 24 | 0.3% | 19.5% | ||
| Q1 24 | 3.2% | 7.5% |
| Q4 25 | $0.67 | $0.69 | ||
| Q3 25 | $0.65 | $1.20 | ||
| Q2 25 | $0.43 | $2.22 | ||
| Q1 25 | $0.51 | $0.83 | ||
| Q4 24 | $0.08 | $1.01 | ||
| Q3 24 | $0.17 | $0.75 | ||
| Q2 24 | $0.02 | $0.94 | ||
| Q1 24 | $0.21 | $0.31 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.5M | $41.3M |
| 総負債低いほど良い | $624.2M | $96.6M |
| 株主資本純資産 | $332.4M | $178.6M |
| 総資産 | $1.4B | $424.7M |
| 負債/資本比率低いほどレバレッジが低い | 1.88× | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $74.5M | $41.3M | ||
| Q3 25 | $85.3M | $49.0M | ||
| Q2 25 | $77.0M | $49.5M | ||
| Q1 25 | $70.4M | $50.0M | ||
| Q4 24 | $67.1M | $55.3M | ||
| Q3 24 | $89.8M | $40.5M | ||
| Q2 24 | $114.6M | $28.8M | ||
| Q1 24 | $98.7M | $33.1M |
| Q4 25 | $624.2M | $96.6M | ||
| Q3 25 | $628.0M | $96.7M | ||
| Q2 25 | $631.7M | $1.8M | ||
| Q1 25 | $635.4M | $1.0M | ||
| Q4 24 | $639.1M | $184.0K | ||
| Q3 24 | $295.2M | $238.0K | ||
| Q2 24 | $312.1M | $292.0K | ||
| Q1 24 | — | $345.0K |
| Q4 25 | $332.4M | $178.6M | ||
| Q3 25 | $311.7M | $162.5M | ||
| Q2 25 | $285.7M | $135.7M | ||
| Q1 25 | $266.0M | $84.3M | ||
| Q4 24 | $246.8M | $65.3M | ||
| Q3 24 | $258.5M | $42.1M | ||
| Q2 24 | $256.6M | $24.8M | ||
| Q1 24 | $270.1M | $3.2M |
| Q4 25 | $1.4B | $424.7M | ||
| Q3 25 | $1.4B | $458.9M | ||
| Q2 25 | $1.4B | $437.7M | ||
| Q1 25 | $1.3B | $372.7M | ||
| Q4 24 | $1.3B | $328.2M | ||
| Q3 24 | $966.3M | $339.1M | ||
| Q2 24 | $982.2M | $307.6M | ||
| Q1 24 | $979.0M | $286.8M |
| Q4 25 | 1.88× | 0.54× | ||
| Q3 25 | 2.01× | 0.60× | ||
| Q2 25 | 2.21× | 0.01× | ||
| Q1 25 | 2.39× | 0.01× | ||
| Q4 24 | 2.59× | 0.00× | ||
| Q3 24 | 1.14× | 0.01× | ||
| Q2 24 | 1.22× | 0.01× | ||
| Q1 24 | — | 0.11× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.4M | $-4.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.3M | $-7.6M |
| FCFマージンFCF / 売上 | 2.2% | -4.0% |
| 設備投資強度設備投資 / 売上 | 3.0% | 1.6% |
| キャッシュ転換率営業CF / 純利益 | 0.70× | -0.29× |
| 直近12ヶ月FCF直近4四半期 | $47.3M | $14.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.4M | $-4.6M | ||
| Q3 25 | $9.3M | $3.3M | ||
| Q2 25 | $21.3M | $16.7M | ||
| Q1 25 | $43.2M | $8.8M | ||
| Q4 24 | $3.1M | $32.7M | ||
| Q3 24 | $12.6M | $12.6M | ||
| Q2 24 | $28.4M | $1.5M | ||
| Q1 24 | $11.4M | $15.6M |
| Q4 25 | $8.3M | $-7.6M | ||
| Q3 25 | $-4.5M | $1.7M | ||
| Q2 25 | $8.1M | $14.6M | ||
| Q1 25 | $35.4M | $5.4M | ||
| Q4 24 | $-4.7M | $30.0M | ||
| Q3 24 | $3.0M | $12.1M | ||
| Q2 24 | $15.4M | $822.0K | ||
| Q1 24 | $1.7M | $14.8M |
| Q4 25 | 2.2% | -4.0% | ||
| Q3 25 | -1.2% | 0.8% | ||
| Q2 25 | 2.1% | 7.6% | ||
| Q1 25 | 10.2% | 4.0% | ||
| Q4 24 | -1.5% | 20.8% | ||
| Q3 24 | 1.2% | 9.7% | ||
| Q2 24 | 5.6% | 0.7% | ||
| Q1 24 | 0.6% | 15.6% |
| Q4 25 | 3.0% | 1.6% | ||
| Q3 25 | 3.8% | 0.8% | ||
| Q2 25 | 3.5% | 1.1% | ||
| Q1 25 | 2.2% | 2.5% | ||
| Q4 24 | 2.5% | 1.8% | ||
| Q3 24 | 3.7% | 0.3% | ||
| Q2 24 | 4.8% | 0.6% | ||
| Q1 24 | 3.7% | 0.9% |
| Q4 25 | 0.70× | -0.29× | ||
| Q3 25 | 0.35× | 0.12× | ||
| Q2 25 | 1.24× | 0.33× | ||
| Q1 25 | 2.07× | 0.46× | ||
| Q4 24 | 0.97× | 1.40× | ||
| Q3 24 | 1.81× | 0.73× | ||
| Q2 24 | 37.80× | 0.07× | ||
| Q1 24 | 1.36× | 2.20× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
